Loading clinical trials...
Loading clinical trials...
The purpose of this study was to give access to postmenopausal women with estrogen sensitive primary breast cancer to exemestane for the adjuvant treatment of breast cancer after the use of tamoxifen ...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Pfizer
NCT07287098 · Breast Neoplasms
NCT07222215 · Estrogen-receptor-positive Breast Cancer, Metastatic Breast Cancer, and more
NCT07230535 · Breast Cancer, Breast Neoplasms, Breast Reconstruction, and more
NCT06380816 · Advanced Solid Tumours, Squamous Cell Carcinoma of Head and Neck, and more
NCT06608446 · Breast Neoplasms
Pfizer Investigational Site
Aalst
Pfizer Investigational Site
Antwerp
Pfizer Investigational Site
Arlon
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions